Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Personalised Risk scOre For Implantation of Defibrillators in Patients With Reduced LVEF≤35% and a Low Risk for Sudden Cardiac Death (PROFID-Reduced)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04540354
Recruitment Status : Not yet recruiting
First Posted : September 7, 2020
Last Update Posted : September 7, 2020
Sponsor:
Information provided by (Responsible Party):
Leipzig Heart Institute GmbH

Brief Summary:
The objective of the study is to demonstrate that in post-MI patients with symptomatic heart failure who receive optimal medical therapy for this condition, and with reduced LVEF ≤ 35% but low risk for SCD according to a personalised risk score, optimal medical therapy without ICD implantation (index group) is not inferior to optimal medical therapy with ICD implantation (control group) with respect to all-cause mortality.

Condition or disease Intervention/treatment Phase
Myocardial Infarction Heart Failure Sudden Cardiac Death Drug: Optimal Medical Therapy (OMT) Device: Implantable cardioverter-defibrillator (ICD) Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2480 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: The PROFID-Reduced trial is an open-label, blinded outcome assessment study. Thus, unblinding proce-dures for investigators are not applicable.
Primary Purpose: Prevention
Official Title: Personalised Risk scOre For Implantation of Defibrillators in Patients With Reduced LVEF≤35% and a Low Risk for Sudden Cardiac Death (PROFID-Reduced)
Estimated Study Start Date : February 1, 2021
Estimated Primary Completion Date : January 31, 2024
Estimated Study Completion Date : December 31, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: Optimal Medical Therapy without ICD device therapy
Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will not receive an ICD device
Drug: Optimal Medical Therapy (OMT)
Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.

Active Comparator: Optimal Medical Therapy with ICD device therapy
Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive an ICD device
Drug: Optimal Medical Therapy (OMT)
Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.

Device: Implantable cardioverter-defibrillator (ICD)

An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).

The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed.





Primary Outcome Measures :
  1. Time from randomisation to the occurrence of all-cause death [ Time Frame: Randomization to end of study (event-driven, expected about 15 months after last patient in) ]

Secondary Outcome Measures :
  1. Time from randomisation to death from cardivascular causes [ Time Frame: Randomization to end of study (event-driven, expected about 15 months after last patient in) ]
  2. Time from randomisation to sudden cardiac death [ Time Frame: Randomization to end of study (event-driven, expected about 15 months after last patient in) ]
  3. Time from randomisation to first hospital readmissions for cardiovascular causes after randomisation [ Time Frame: Randomization to end of study (event-driven, expected about 15 months after last patient in) ]
  4. Average length of stay in hospital during the study period [ Time Frame: Randomization to end of study (event-driven, expected about 15 months after last patient in) ]
  5. Quality of life (EQ-5D-5L) trajectories over time [ Time Frame: At baseline and 6-month intervals thereafter ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18 years.
  • Documented history of myocardial infarction either as ST segment elevation myocardial infarction (STEMI) or as non-ST segment elevation myocardial infarction (NSTEMI).
  • Symptomatic heart failure with NYHA class II or III.
  • On Optimal Medical Therapy (OMT) for at least 3 months prior to enrolment.
  • LVEF ≤ 35% at transthoracic echocardiography or cardiac magnetic resonance imaging (MRI).
  • Predicted personalised annual risk of SCD according to the clinical risk calculator ≤2.5%.
  • Signed informed consent.

Exclusion Criteria:

  • Class I or IIa indication for implantation of an ICD for secondary prevention of sudden cardiac death and ventricular tachycardia (according to the 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, see Appendix V).
  • Ventricular tachycardia induced in an electrophysiologic study.
  • Unexplained syncope when ventricular arrhythmia is suspected as the cause of syncope.
  • Conclusive clinical indication for CRT (class I or IIa indication according to the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure)
  • Carrying any implanted cardiac pacemaker, defibrillator or CRT device.
  • Violation of instruction for use (IFU) of the selected ICD device by at least one of the random group treatments.
  • Hospitalised with unstable heart failure with NYHA class IV within 1 month prior to enrolment.
  • Acute coronary syndrome or cardiac revascularization therapy by coronary angioplasty or coronary artery bypass grafting within 3 months prior to enrolment.
  • Cardiac valve surgery or percutaneous cardiac valvular intervention such as transcatheter aortic valve replacement or transcatheter mitral valve repair performed within 3 months prior to enrolment.
  • On the waiting list for heart transplantation.
  • Any known disease that limits life expectancy to less than 1 year.
  • Participation in another clinical trial, either within the 3 months prior to enrolment or still on-going (participation in sub-studies connected to this trial is permitted).
  • Previous participation in PROFID-Reduced.
  • Drug abuse or clinically manifest alcohol abuse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04540354


Contacts
Layout table for location contacts
Contact: Gerhard Hindricks, MD +493418651410 Gerhard.Hindricks@helios-gesundheit.de
Contact: Nikolaos Dagres, MD +49341865252612 Nikolaos.Dagres@helios-gesundheit.de

Sponsors and Collaborators
Leipzig Heart Institute GmbH
Investigators
Layout table for investigator information
Principal Investigator: Gerhard Hindricks, MD Department of Electrophysiology, Leipzig Heart Center at University of Leipzig
Principal Investigator: Nikolaos Dagres, MD Department of Electrophysiology, Leipzig Heart Center at University of Leipzig
Additional Information:
Layout table for additonal information
Responsible Party: Leipzig Heart Institute GmbH
ClinicalTrials.gov Identifier: NCT04540354    
Other Study ID Numbers: LHI-2020-02
847999 ( Other Grant/Funding Number: European Union's Horizon 2020 research and innovation programme )
First Posted: September 7, 2020    Key Record Dates
Last Update Posted: September 7, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Leipzig Heart Institute GmbH:
Myocardial Infarction
Heart Failure
Sudden Cardiac Death
Implantable Cardioverter Defibrillator
PROFID
Personalized Medicine
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Myocardial Infarction
Death, Sudden, Cardiac
Infarction
Death
Heart Diseases
Cardiovascular Diseases
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Vascular Diseases
Heart Arrest
Death, Sudden